National Centre for
Pharmacoeconomics
NCPE Ireland
About Us
Current Staff
News
Glossary
Contact Us
Vacancies
Home
Submission Process
HTA Guidelines
Process Flowchart
Submission Templates
Pharmacoeconomic Evaluations
Drugs
Vaccines
Diagnostics and Other Technologies
Publications
Peer Reviewed Papers
Abstracts
Reports
Research
Pharmacoeconomic Research
Education
COVID-19
For Patients
Drugs
:
C
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
R
S
T
U
V
Z
C1inhibitor (human) (Cinryze®)
Cabazitaxel (Jevtana®)
Cabotegravir (Vocabria®) in combination with rilpivirine (Rekambys®). HTA ID: 21026
Cabozantinib (Cabometyx®)
Cabozantinib (Cabometyx®) in combination with nivolumab (Opdivo®) for 1L RCC. HTA ID: 22018
Cabozantinib (Cometriq®)
Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar ®)
Camellia sinensis, folium (green tea leaf) (Catephen 10%®)
Canagliflozin (Invokana®)
Cannabidiol (Epidyolex®) for the treatment of Dravet Syndrome. HTA ID: 20004
1
2
3
4
5
Next Page
health check